Investors who want to play the really interesting stories in med-tech have to be ready to act fast or step up when times look uncommonly tough. That's about the only way to get a decent valuation on stocks like Intuitive Surgical (Nasdaq:ISRG), Cepheid (Nasdaq:CPHD) or Illumina (Nasdaq:ILMN), and that seems largely true for animal and food safety specialist Neogen (Nasdaq:NEOG). Although valuation and earnings quality are still problematic here, these shares also highlight the importance of being up-to-date on research and able to pull the trigger quickly.

Investopedia Markets: Explore the best one-stop source for financial news, quotes and insights.

A Disappointing Second Quarter
Although Neogen doesn't generally step far out of line, this quarter was a notable exception. Revenue rose just 2% this quarter, not only missing the averaged estimate but missing the low-end estimate as well. Animal safety revenue was up just 1%, due at least in part to lower activity in the GeneSeek agricultural genomics business. Food safety was hardly stellar, though, as revenue was up just over 3% this quarter.

Profits were even more disappointing than growth. Gross margin slid almost a point, and management blamed it on a mix shift (which would be consistent with lower sales of more profitable genomics services). Operating income fell 16% and operating margin four points as the company put more money into its sales and marketing efforts in the hopes of driving better revenue growth. (For related reading, see A Primer On The Biotech Sector.)

Mostly Just a Pause
There could be plenty of explanations for this quarter's poor performance that don't ding the long-term story. The company is annualizing tough comps from myotoxin testing in corn and there are rumors that there's another poor quality crop out there that could boost sales later in this fiscal year.

At the same time, the company is seeing some momentum in other kinds of toxin testing and will soon be pushing the ANSR molecular diagnostics platform for foodborne pathogens. This ANSR could be an interesting platform and grab business from the likes of Bio-Rad (NYSE:BIO) as it offers a simple and quick testing methodology that's easy on equipment and labor.

There's also the question of the genomics business. Neogen is partnered with Illumina and seems to be seeing some of the same problems - including lower government spending and a tough European markets. Longer term, though, it's easy to be bullish on agrigenomics even with companies like Life Technologies (Nasdaq:LIFE) and Luminex (Nasdaq:LMNX) active in the space.

Still Some Issues to Resolve
Neogen's stock may have overreacted to one quarter's disappointment, but then a lot is baked into the price. Neogen generates good returns on capital, but a lot of its growth has long been dependent on serial acquisitions. For a company that needs to prove it can produce organic double-digit growth, this quarter was a definite setback.

Valuation is likewise an issue. Not unlike Meridian Bioscience (Nasdaq:VIVO) or IDEXX Labs (Nasdaq:IDXX), Neogen has a great business but a valuation that goes beyond "healthy" and a fairly sluggish free cash flow margin.

Be Ready, Move Fast
Quality and scarcity are two valid reasons for Neogen to be richly valued. There may also be acquisition expectations at work here as well. Unfortunately, there is only a limited number of likely potential suitors - companies with a presence in food safety like Waters (NYSE:WAT), Mettler Toledo (NYSE:MTD) or Bio-Rad arguably don't need or want the animal business, and companies with animal care businesses (including large pharmas like Sanofi (NYSE:SNY)) don't need the food safety.

In the immediate aftermath of the earnings release, Neogen shares traded as low as $26 before steadily recovering during the day on Thursday. Near the $26 level, it was an interesting play on a company that generates good returns from underserved markets. At $30, it's a harder sale given that it presupposes a lot of top-line growth and improvements in free cash flow production. For now, then, this is a good example of the virtues of being prepared and ready to move - bargains don't always hang around very long. (For related reading, see How To Do Quantitative Analysis On Biotech Companies.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

At the time of writing, Stephen D. Simpson did not own shares in any of the companies mentioned in this article.

Related Articles
  1. Stock Analysis

    Net Neutrality: Pros and Cons

    The fight over net neutrality has become an amazing spectacle. But at its core, it's yet another skirmish in cable television's war to remain relevant.
  2. Personal Finance

    Protect Your Home From Medicaid Liens

    Plan ahead for long-term care needs to protect your home and your estate.
  3. Personal Finance

    A Day in the Life of an Equity Research Analyst

    What does an equity research analyst do on an everyday basis?
  4. Mutual Funds & ETFs

    ETF Analysis: PowerShares S&P 500 Downside Hedged

    Find out about the PowerShares S&P 500 Downside Hedged ETF, and learn detailed information about characteristics, suitability and recommendations of it.
  5. Mutual Funds & ETFs

    ETF Analysis: ProShares Large Cap Core Plus

    Learn information about the ProShares Large Cap Core Plus ETF, and explore detailed analysis of its characteristics, suitability and recommendations.
  6. Mutual Funds & ETFs

    ETF Analysis: iShares Core Growth Allocation

    Find out about the iShares Core Growth Allocation Fund, and learn detailed information about its characteristics, suitability and recommendations.
  7. Mutual Funds & ETFs

    ETF Analysis: iShares MSCI USA Minimum Volatility

    Learn about the iShares MSCI USA Minimum Volatility exchange-traded fund, which invests in low-volatility equities traded on the U.S. stock market.
  8. Stock Analysis

    Should You Follow Millionaires into This Sector?

    Millionaire investors—and those who follow them—should take another look at the current economic situation before making any more investment decisions.
  9. Professionals

    What to do During a Market Correction

    The market has what? Here's what you should consider rather than panicking.
  10. Mutual Funds & ETFs

    ETF Analysis: Vanguard Mid-Cap Value

    Take an in-depth look at the Vanguard Mid-Cap Value ETF, one of the largest and most popular mid-cap funds in the U.S. equity space.
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. Hard-To-Sell Asset

    An asset that is extremely difficult to dispose of either due ...
  3. Sucker Yield

    When an investor has essentially risked all of his capital for ...
  4. PT (Perseroan Terbatas)

    An acronym for Perseroan Terbatas, which is Limited Liability ...
  5. Ltd. (Limited)

    An abbreviation of "limited," Ltd. is a suffix that ...
  6. BHD (Berhad)

    The suffix Bhd. is an abbreviation of a Malay word "berhad," ...
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>

You May Also Like

Trading Center

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!